To determine whether the extent of leukoaraiosis, a composite marker of baseline brain integrity, differed between patients with TIA with diffusion-weighted imaging (DWI) evidence of infarction (transient symptoms with infarction [TSI]) and patients with ischemic stroke.
fied by the volume of leukoaraiosis contributes to variability in poststroke functional outcome. 6 -9 We hypothesized that the extent of leukoaraiosis would be smaller in TSI compared to ischemic stroke and partially explain why some individuals develop TSI and others develop ischemic stroke after brain infarction.
METHODS Patient population. We retrospectively analyzed consecutive patients presenting to a single tertiary care center with symptoms of TIA or stroke and acute brain infarction on diffusion-weighted imaging (DWI) obtained within 24 hours of symptom onset, over a 3-year period. Patients were identified from a prospectively maintained database that included all consecutive admissions with imaging evidence of acute brain infarction. We excluded patients in whom the quality of MRI was not sufficient to reliably assess the presence of acute infarction or volume of leukoaraiosis. Because large infarcts are invariably associated with ischemic stroke rather than TSI, 2 we restricted our study to the population of ischemic stroke patients with infarcts that were comparable in size to those in TSI. Hence, the study population was composed of TSI and ischemic stroke patients with similar infarct volumes (figure 1). We use the term TSI to designate patients with focal symptoms lasting less than 24 hours who had DWI evidence of acute infarction. 2 Patients with clinical symptoms lasting more than 24 hours were classified as ischemic stroke. 10 Symptom duration was estimated from neurologists' notes based on neurologic examination findings and interviews with patients and their reliable observers. Data collection. We collected data on baseline patient characteristics and published predictors of short-term stroke outcome through chart review. These predictors included age, 11 gender, 12 stroke risk factors, 13, 14 admission NIH Stroke Scale score, 15 thrombolytic treatment, 16 and etiologic stroke subtype. 17 Stroke etiology was classified using the Causative Classification of Stroke (CCS) system. 18 We also recorded the time from symptom onset to MRI, the number of acute infarcts, the location of acute infarcts, and whether there were chronic infarcts on MRI or arterial occlusion on admission CT or magnetic resonance angiography in major branches of the circle of Willis. We classified infarct location based on visual assessment of images into 6 categories: brainstem, cerebellum, the basal region supplied by deep penetrating arteries, subcortical white matter region, cortex, and multiple regions.
Image acquisition and analysis. MRI was performed by 1.5 T GE Signa (GE Medical Systems, Milwaukee, WI) or Siemens Sonata (Siemens Medical Solutions, Erlangen, Germany) scanners using the image acquisition and processing protocols that have been summarized in detail previously. 19 Acute ischemic lesion volume on DWI and leukoaraiosis volume on fluidattenuated inversion recovery (FLAIR) images acquired within 24 hours of symptom onset were determined using semiautomated region of interest outlining and volume calculation tools on the MRIcro software (www.mricro.com, University of Nottingham, UK). 9 DWI and leukoaraiosis volume measurements were performed by investigators blinded to the clinical status (TSI or ischemic stroke). We measured leukoaraiosis volume separately in each hemisphere and calculated the sum for use in further analyses. We defined leukoaraiosis as hyperintense white matter regions on FLAIR images excluding the convolutional white matter, U-fibers, corpus callosum, internal capsule, anterior commissure, and infratentorial regions. 20 We also excluded chronic white matter infarcts that clearly conformed to a vascular territory. All volume calculations were normalized according to the intracranial area using the following formula 21 : normalized lesion volume ϭ lesion volume ϫ mean intracranial area of the population/intracranial area of an individual patient. Intracranial area was measured by outlining the inner tabula on the midsagittal T1 images. The methods used for calculation of infarct volume, leukoaraiosis volume, and intracranial area were previously shown to have high interrater reliability (intraclass correlation coefficient: 0.99 for infarct volume, 0.98 for leukoaraiosis volume, and 0.97 for intracranial area). [21] [22] [23] Statistical analysis. All numerical variables are expressed as median (interquartile range [IQR] ). The differences between ischemic stroke and TSI cohorts were assessed by 2 test for categorical variables and Mann-Whitney U test for continuous variables. A logistic regression model was used for multivariable analysis. The model included ischemic stroke vs TSI as the dependent variable. All variables with a p value of Ͻ0.05 in bivariate analyses (history of hypertension, history of atrial fibrillation, CCS stroke subtype, IV tissue plasminogen activator treatment, DWI lesion location, arterial cutoff in proximal branches of the circle of Willis, normalized DWI lesion volume, and normalized leukoaraiosis volume) were introduced into the model as independent variables. All categorical variables were entered as dummy variables into the model. Data were examined for collinearity. Associations were presented as odds ratios (OR) with corresponding 95% confidence intervals (95% CI). A 2-tailed p Probability
of transient symptoms with infarction (TSI) decreases as diffusion-weighted imaging (DWI) volume increases
Circles represent individual data points. Lines represent the probability curve and 95% confidence interval. The area left to the vertical dotted line (DWI volume ϭ 13.7 mL) represents the region of overlapping infarct volumes in subjects with TSI and ischemic stroke.
value of Ͻ0.05 was considered significant. Statistical analyses were performed using SPSS 16.0.
Standard protocol approvals, registrations, and patient consents. The study was approved by the local Human Studies
Committee.
RESULTS
A total of 1,085 consecutive patients with DWI evidence of acute infarction within the first 24 hours of symptom onset were admitted during the study period. We excluded 57 patients with either missing FLAIR images or FLAIR images with motion artifacts or extensive chronic ischemic lesions that prevented reliable assessment of the boundaries of leukoaraiosis. The remaining population comprised 153 patients with TSI and 875 patients with ischemic stroke. Infarct volume ranged between 0.1 mL and 13.7 mL in TSI and 0.1 mL and 367.1 mL in ischemic stroke. In 354 of the 875 patients with ischemic stroke, the infarct volume was within the TSI range (smaller than 13.7 mL, figure 1 ). Thus, the final study population was composed of 153 patients with TSI and 354 patients with ischemic stroke.
In the TSI subjects, the median symptom duration was 1 hour (IQR 10 minutes-4 hours). Symptoms lasted less than 1 hour in 71 (46.4%), 1 hour to 2 hours in 40 (26.1%), and longer than 2 hours in 42 (27.4%) patients. There were only 6 patients with symptoms lasting more than 12 but less than 24 hours. Leukoaraiosis volume correlated with symptom duration in patients with TSI (r ϭ 0.20, p ϭ 0.015). Table 1 summarizes demographic, clinical, and imaging characteristics of TSI and ischemic stroke populations. There was no difference in baseline features between the study population and the population excluded due to insufficient quality of images. Patients with ischemic stroke more frequently had a history of hypertension, atrial fibrillation, small artery occlusion as the etiologic stroke mechanism, isolated deep or brainstem infarct, arterial cutoff on angiography, and more often received IV tissue plasminogen activator treatment. Patients with TSI were more likely to have isolated cortical infarcts and infarcts restricted to the subcortical white matter.
The normalized median infarct volume on DWI was 0.82 mL (IQR 0.32-2.93 mL) in ischemic stroke and 0.31 mL (IQR 0.11-0.95 mL) in TSI ( p Ͻ 0.001). Patients with ischemic stroke showed more extensive leukoaraiosis as compared to patients with TSI (figure 2); the normalized median leukoaraiosis volume was 3.5 mL (IQR 1.2-8.6 mL) in ischemic stroke and 1.2 mL (IQR 0.2-4.7 mL) in TSI ( p Ͻ 0.001). In multivariable logistic regression, leukoaraiosis volume, infarct volume, and infarct location were independently associated with TSI vs ischemic stroke status (table 2). The probability of ischemic stroke increased substantially with increasing leukoaraiosis volume. Ischemic stroke was at least 10 times more likely to develop than TSI when leukoaraiosis volume exceeded 30 mL (figure 2). In contrast, in patients with no leukoaraiosis, the probability of TSI and ischemic stroke were almost identical.
The relationship between leukoaraiosis volume and clinical status persisted in a separate model where the TSI population was restricted to only those with symptoms that lasted less than 1 hour (OR 1.06 [95% CI 1.00 -1.12], p ϭ 0.034). Likewise, the regression model repeated after excluding patients with chronic white matter infarcts demonstrated that leukoaraiosis volume was still an independent predictor of clinical status (OR 1.04 [95% CI 1.00 -1.09], p ϭ 0.040). DISCUSSION We have shown that among patients presenting with acute infarction on DWI, those with stroke symptoms that resolve within 24 hours have smaller leukoaraiosis volume compared to patients with persistent symptoms indicating an ischemic stroke. The median normalized leukoaraiosis volume was approximately 3 times higher in patients with ischemic stroke as compared to TSI. In addition to leukoaraiosis volume, infarct size and infarct location also differed between TSI and ischemic stroke; the probability of ischemic stroke increased with rising infarct volume. Infarcts that included critical structures with compact anatomic organization such as the brainstem or in locations where typical lacunar infarcts occurred were also more likely to be associated with ischemic stroke. While infarct size and location are important, they together explain only half of the variability in functional outcome in patients with ischemic stroke. 24 Our data suggest that the brain's intrinsic capacity to recover from ischemic brain injury may be in part determined by the extent of leukoaraiosis, which is also known to contribute to the variability in outcome. 6 -9 Pathology findings in leukoaraiosis include, among other things, axonal changes ranging from mild demyelination to severe axonal disruption. 25 The severity of these pathologic changes correlates with the extent of leukoaraiosis on MRI. 26 Published evidence from studies using transcranial magnetic stimulation, fMRI, and diffusion tensor imaging suggests that recruitment and reorganization of ipsilesional and contralesional brain regions during poststroke recovery requires the presence of intact connections between different parts of the brain. [27] [28] [29] An in silico model of activity-dependent plasticity has supported this view, showing that axonal dysfunction caused by blocking of the propagation of action potentials between neurons results in deficits in pruning and recovery of functional synapses and this in turn produces a negative impact on adaptive plasticity that is much greater than the impact of gray matter injury. 30 The view that leukoaraiosis impairs the brain's ability to compensate for the lost function is supported by multiple recent studies indicating that the extent of leukoaraiosis correlates with poor functional outcome and low quality of life after ischemic stroke. 6 -8 We have previously shown that leukoaraiosis volume is a predictor of modified Rankin Scale score at 6 months following ischemic stroke after controlling for age, infarct volume, etiologic stroke mechanism, initial stroke severity, and preventive stroke treatment; the highest quartile of leukoaraiosis volume is associated with a 1.5-fold higher modified Rankin Scale score as compared with the lowest quartile. 9 The current data offer additional evidence that leukoaraiosis volume is a marker for the brain's capacity for rapid and complete recovery of the lost function.
It is notable that clinical recovery in TSI is a strikingly rapid process. In the present dataset, 46% of
Figure 2 Probability of transient symptoms with infarction (TSI) decreases as leukoaraiosis volume increases
The circles represent individual data points. Lines represent the probability curve and 95% confidence interval. DWI ϭ diffusion-weighted imaging. TSIs lasted less than 1 hour and another 26% lasted between 1 and 2 hours. The majority of TSI events lasting less than 1 hour lasted often only 1 to 10 minutes (66%). It is thus plausible to presume that most small infarcts (i.e., those within the region of overlap in figure 1 ) either recover completely and very rapidly often within minutes or recover gradually and often only partially in longer than 24 hours. This tendency toward bimodal distribution of symptom duration in small infarcts suggests that there is a threshold in the brain's capacity to regain the lost function, which, when exceeded, symptoms that would otherwise last only for a few minutes could persist for more than 24 hours. The association between ischemic stroke and increasing leukoaraiosis volume may suggest that leukoaraiosis impairs the brain's reserve capacity so that small infarcts could easily overcome the threshold to result in lasting ischemic stroke symptomatology.
Leukoaraiosis is not only a predictor of functional outcome but also has been reported to predict future episodes of stroke in individuals with or without previous stroke. [31] [32] [33] It has been suggested that leukoaraiosis reflects an increased burden of stroke risk factors and therefore identifies individuals at high risk of stroke. 31 Data from the Atherosclerosis Risk in Communities study, on the other hand, challenges this view by showing that the association between leukoaraiosis and stroke risk is independent of conventional stroke risk factors such as hypertension, diabetes, and cigarette smoking. 33 Our findings may shed light into the mechanism of increased stroke risk in individuals with leukoaraiosis by suggesting that leukoaraiosis-mediated impaired capacity to compensate for injury results in occurrence of symptomatic stroke in an event of acute infarction. This view is further supported by evidence indicating that leukoaraiosis confers an increased perioperative symptomatic stroke risk after procedures that are known to be associated with high rate of brain embolism such as carotid artery stenting, 34 carotid endarterectomy, 34 intraoperative shunt placement during carotid endarterectomy, 35 and total aortic arch replacement. 36 Future research examining leukoaraiosis load-by-treatment efficacy interaction in conditions associated with small brain infarcts such as those occurring following carotid endarterectomy and stenting might demonstrate practical utility of the current findings. Leukoaraiosis information could also be used to generate predictive algorithms (along with other independent predictors of clinical outcome) to optimize benefit and minimize risk from thrombolytic therapy. Such models might identify individuals with high likelihood of early spontaneous recovery in whom withholding thrombolytic therapy could be justified. In contrast, in patients with extensive leukoaraiosis, the high risk of intracranial hemorrhage might outweigh the benefit by thrombolysis that accrues from reduced risk of developing disabling permanent deficit. 37 Our findings are subject to a number of limitations. First, time-based categorization of clinical status (TSI vs ischemic stroke) might have introduced ascertainment bias in subjects with small infarcts who had symptoms lasting for around 24 hours. Nevertheless, the observed association between leukoaraiosis and clinical phenotype was strong and persisted in sensitivity analyses in subsets with symptoms that lasted for Ͻ1 hour vs Ͼ24 hours. Second, although we stratified infarct location into anatomically distinct and clinically important categories, our approach did not take into account the regional differences within each category. A more detailed segmentation of the brain employing a voxelby-voxel approach might provide more accurate estimation of the impact of location on clinical phenotype, and highlight specific regions of the brain where the impact of leukoaraiosis on persistence of symptoms might be highest. Such methods demand large datasets for adequate sampling of each brain compartment. Finally, patients who had MRI with motion artifacts were excluded from the study. This, however, did not appear to have caused a significant selection bias as none of the baseline clinical features listed in table 1 were significantly different between the study population and the excluded patients.
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